Skip to main content
Equibles
PEN logo

PEN · Penumbra Inc

Track PEN — free

Use PEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$317.55 -0.45 (-0.14%) At close · Oct 2
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$12.56B
Shares
39.39M
Volume · Oct 2 239.68K Avg daily vol (3M) 342.99K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$317.55 Open$318.37 Day$316.78–318.37 52W close$225.54–359.40 Avg vol 30d353K Short int1.8M · 4.6% float · 7.2d Short vol51% Last earningsJul 30, 2026 DataJan 2020–Oct 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 30, 2026 Est · unconfirmed · in 4 wks
Latest filing: 10-Q
filed Jul 30, 2026
Q3 2025 earnings call transcript
call held Nov 5, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.50B
Trailing 12 months
Net income (TTM)
$160.59M
Trailing 12 months
Revenue growth YoY
+14.9%
Year over year
Operating margin
12.4%
Trailing 12 months
P / E (TTM)
78.1
Trailing earnings · reciprocal yield 1.3%
FCF yield
1.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$205.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+27.4%
Trailing year
Short interest
4.6%
Latest settlement · 7.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very Low
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −1%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 69%
mid-range
Momentum
relative strength
Weak
1-month return −1%
trailing
6-month return −4%
trailing
YTD return +2%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $322 › 200d $327 — 200d above 50d
Institutional flow Accumulating
3 of 454 funds reported for Sep 30 · net +1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.58% of float · ▲ +4.3% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
454 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +17%
Y/Y
Gross margin 67%
expanding
EPS growth +1156%
Y/Y
Free cash flow $174.9M
Valuation P/E 78.4
rich
Buyback $100.0M
remaining
Quant / Vol
risk profile
Very Low
Volatility 28%
annualized · 1-yr
Max drawdown −14%
past year
ATR 0.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Prior guidance period ended · from the 8-K filed Jan 15, 2026
Reported revenue · full year 2025 $1.4B
Reported revenue growth · full year 2025 17.3% – 17.5%
Guided vs delivered · last 4 settled
Total revenue full year 2024
guided $1.18B – $1.2B
$1.19B In line
Total company revenue full year 2023
guided $1.05B – $1.07B
$1.06B In line
Total revenues full year 2022
guided $860M – $875M
$847.13M Miss −2.3%
2021 revenue 2021
guided $735M – $740M
$747.59M Beat +1.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−1% Neutral
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
69% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $322 › 200d $327 — 200d above 50d
Institutional flow Accumulating
3 of 454 funds reported for Sep 30 · net +1 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.58% of float · ▲ +4.3% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
454 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $226 Now $318 · 69% Range high $359
vs 200-day avg -3% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PEN
Penumbra Inc
this stock
$12.56B +2.1% +17.5% 78.4 4.6%
ABT
Abbott Laboratories
 $174.90B -22.2% +5.7% 28.1 1.1%
MDT
Medtronic plc
 $113.38B -10.1% +8.4% 21.8 1.3%
SYK
Stryker Corp
 $104.47B -21.6% +11.2% 28.2 2.0%
BSX
Boston Scientific Corp
 $63.59B -55.3% +12.5% 17.8 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
454
% held
88.7%
Reported
3 of 454
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
350
View
Short & Settlement
Short Interest Rising
Shares short
1.8M
Days to cover
7.2d
Change
+74.4K sh
View
Short Volume
Short vol %
51%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$320
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Jul 10, 2025
View
Financials
Financials
Revenue (FY)
$1.4B
Net income (FY)
$177.7M
EPS diluted
$4.52
View
Buybacks
Authorized
$200.0M
Remaining
$100.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 30, 2026
This year
10
View
Proposed Sales
Value
$32.8K
Shares
100
Filed
Apr 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Jul 30, 2026
View

Performance

5D 20D 120D MTD YTD
PEN -0.4% -1.1% -4.2% -0.3% +2.1%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -0.2% -0.7% -16.4% -1.2% -10.7%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$200.00M
Spent (derived)
$100.00M
Remaining
$100.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1321732 CUSIP 70975L107 13F (30d) 14 filings 12 filers Visit website Investor relations